中国医师杂志
中國醫師雜誌
중국의사잡지
JOURNAL OF CHINESE PHYSICIAN
2014年
8期
1071-1075
,共5页
张建%石乔%张家耀%张勇%李锦貌%张昌威%丁俊%廖康恕%李邵琼
張建%石喬%張傢耀%張勇%李錦貌%張昌威%丁俊%廖康恕%李邵瓊
장건%석교%장가요%장용%리금모%장창위%정준%료강서%리소경
川芎嗪/治疗应用%胰腺炎/药物疗法%急性病%治疗结果%随机对照试验%Meta分析
川芎嗪/治療應用%胰腺炎/藥物療法%急性病%治療結果%隨機對照試驗%Meta分析
천궁진/치료응용%이선염/약물요법%급성병%치료결과%수궤대조시험%Meta분석
TETRAMETHYLPYRAZINE/therapeutic use%Pancreatitis/drug therapy%Acute disease%Treatment outcome%Randomized controlled trial%Meta-analysis
目的 通过Meta分析的方法对川芎嗪治疗急性胰腺炎的疗效进行评价.方法 计算机检索WANFANG(1999～2013)、VIP(1989 ～2013)、CNKI(1994 ～ 2013)及CAJD数据库中关于川芎嗪治疗胰腺炎的临床随机对照试验(RCT),对符合要求的RCT进行Meta分析.结果 最终纳入13篇RCT,有1 083例患者符合纳入标准.Meta分析结果显示,川芎嗪治疗组的临床疗效(总效应Z =4.33,OR =4.72,95％ CI2.34～9.53,P＜0.01)、并发症(总效应Z=5.50,OR=0.29,95％ CI0.19 ～0.45,P＜0.01)、死亡率(总效应Z=2.18,OR =0.50,95％ CI0.27 ～ 0.93,P=0.03)、住院时间(总效应Z=4.66,MD=-5.43,95％ CI-7.71 ～-3.15,P＜0.01)均明显优于对照组(P＜0.05).结论 在常规综合治疗基础上,川芎嗪对急性胰腺炎疗效确切,其可显著地提高AP的临床疗效,缩短患者住院时间,降低并发症,减少死亡率.
目的 通過Meta分析的方法對川芎嗪治療急性胰腺炎的療效進行評價.方法 計算機檢索WANFANG(1999～2013)、VIP(1989 ～2013)、CNKI(1994 ～ 2013)及CAJD數據庫中關于川芎嗪治療胰腺炎的臨床隨機對照試驗(RCT),對符閤要求的RCT進行Meta分析.結果 最終納入13篇RCT,有1 083例患者符閤納入標準.Meta分析結果顯示,川芎嗪治療組的臨床療效(總效應Z =4.33,OR =4.72,95％ CI2.34～9.53,P＜0.01)、併髮癥(總效應Z=5.50,OR=0.29,95％ CI0.19 ～0.45,P＜0.01)、死亡率(總效應Z=2.18,OR =0.50,95％ CI0.27 ～ 0.93,P=0.03)、住院時間(總效應Z=4.66,MD=-5.43,95％ CI-7.71 ～-3.15,P＜0.01)均明顯優于對照組(P＜0.05).結論 在常規綜閤治療基礎上,川芎嗪對急性胰腺炎療效確切,其可顯著地提高AP的臨床療效,縮短患者住院時間,降低併髮癥,減少死亡率.
목적 통과Meta분석적방법대천궁진치료급성이선염적료효진행평개.방법 계산궤검색WANFANG(1999～2013)、VIP(1989 ～2013)、CNKI(1994 ～ 2013)급CAJD수거고중관우천궁진치료이선염적림상수궤대조시험(RCT),대부합요구적RCT진행Meta분석.결과 최종납입13편RCT,유1 083례환자부합납입표준.Meta분석결과현시,천궁진치료조적림상료효(총효응Z =4.33,OR =4.72,95％ CI2.34～9.53,P＜0.01)、병발증(총효응Z=5.50,OR=0.29,95％ CI0.19 ～0.45,P＜0.01)、사망솔(총효응Z=2.18,OR =0.50,95％ CI0.27 ～ 0.93,P=0.03)、주원시간(총효응Z=4.66,MD=-5.43,95％ CI-7.71 ～-3.15,P＜0.01)균명현우우대조조(P＜0.05).결론 재상규종합치료기출상,천궁진대급성이선염료효학절,기가현저지제고AP적림상료효,축단환자주원시간,강저병발증,감소사망솔.
Objective To investigate the effectiveness of tetramethylpyrazine in the treatment of severe acute pancreatitis (SAP),with a meta-analysis on the published data.Methods A comprehensive search was performed in WANFANG (1999 ～ 2013),VIP (1989 ～2013),CNKI (1994 ～ 2013),and CAJD databases to collect the randomized controlled trials (RCTs) that used tetramethylpyrazine in the treatment of SAP.Those RCTs were analyzed with meta-analysis method.Results A total of 1 083 patients was analyzed in the 13 RCTs that met the inclusion criteria.The meta-analysis results suggested that,compared to the control group,patients had a significantly clinical efficacy (test for overall effect:Z =4.33,OR =4.72,95％ CI 2.34 ～ 9.53,P ＜ 0.01),lower complication (test for overall effect:Z =5.50,OR =0.29,95％ CI 0.19 ～ 0.45,P ＜ 0.01),less hospital stay (test for overall effect:Z =2.18,OR =0.50,95％ CI0.27 ～0.93,P =0.03),and hospital death (test for overall effect:Z =4.66,MD =-5.43,95％ CI-7.71 ～-3.15,P ＜ 0.01) in tetramethylpyrazine group (P ＜ 0.05).Conclusions On the basis of conventional therapy,the effectiveness of tetramethylpyrazine is positive,it is able to significantly increase clinical efficacy with a low complication,decrease hospital death,and shorten hospital stay.
